The latest flow-through cell dissolution tester that solves various issues of previous flow-through cells, compliant with the Japanese Pharmacopoeia Dissolution Test Method 3.
The flow-through cell dissolution tester is widely applied to poorly soluble, controlled-release, and sustained-release formulations. With the evolution of new drug delivery platforms, USP Apparatus 4 is ideal for studying the dissolution profiles of solid, liquid, oral, and non-oral formulations, as well as stents and implants. This device allows for flexible configurations, making it suitable for a wide variety of dissolution conditions/cells/formulations/hydrodynamics/sink conditions/flow rates. USP Apparatus 4 is the optimal device to meet the needs of recent changes in dissolution testing.
Inquire About This Product
basic information
Reasons for selecting USP Apparatus 4: ● USP Apparatus 4 is an ideal choice for poorly soluble drugs. ● USP Apparatus 4 is the best method for dissolution in large volumes of test solution to achieve infinite sink conditions. ● In IVIVC studies, automatic exchange of test solutions for solid and liquid formulations can be easily realized. ● Flow rates can be easily adjusted, enabling "accelerated" testing studies. ● Many issues such as tablet floating and adhesion are resolved.
Price range
Delivery Time
Applications/Examples of results
The USP device 4 can easily perform the following dissolution tests: • Tablets • Capsules • Powders/Granules/Active Pharmaceutical Ingredients/Bead formulations • Injectable suspensions • Suppositories/Soft gelatin capsules • Microspheres / Liposomes / Nanoparticles • Inhalation drugs
catalog（1）
Download All Catalogs
Company information
Aivic Research was established with the aim of contributing to the improvement of healthcare by helping to enhance the data accuracy of dissolution testing through the provision of excellent dissolution testers and dissolution tester inspection services, as well as introducing the latest dissolution testing information by utilizing various pipes from overseas, thereby supporting the development of the pharmaceutical industry in Japan.